contractpharmaApril 03, 2020
Tag: Fujifilm , iPSC , drug discovery and development
FUJIFILM Cellular Dynamics, Inc. (FCDI), a developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, and FUJIFILM Irvine Scientific, Inc., a provider of cell culture media, will sell iCell products under the FUJIFILM "Discovery Research" organization (part of FUJIFILM Irvine Scientific).
"At Fujifilm we are dedicated to helping customers accelerate their innovation and discoveries to advance research that can result in drug discovery and development," said Takeshi Yamamoto, CEO, FUJIFILM Cellular Dynamics, Inc. "By joining forces with FUJIFILM Irvine Scientific to bring our iCell products to customers, we can now leverage synergies and strengths to benefit our partners and ultimately, drive even greater progress in the field."
FUJIFILM Irvine Scientific is a developer and manufacturer of cell culture media for biopharmaceuticals, cell and gene therapy, regenerative medicine and reproductive medicine.
While access to FUJIFILM Irvine Scientific’s worldwide distribution channels is the first step, the two Fujifilm Group companies will also work together on introducing new joint product kits in the future.
"Fujifilm’s expertise in the life sciences supports drug development from early phase research through to commercialization," said Yutaka Yamaguchi, CEO, FUJIFILM Irvine Scientific. "Fujifilm Group’s resources allow us to tap our collective pool of knowledge and provide complete end-to-end solutions for our customers. Together, we can do more, faster and better."
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: